By Connor Hart
Shares of Insmed rose after the company disclosed what it called positive topline results from a study of its treatment for pulmonary arterial hypertension, or high blood pressure in the lungs.
The stock jumped 20%, to $85, in pre-market trading Tuesday. Through Monday's close, shares have gained 18% in the past year.
The biopharmaceutical company said its study evaluating the efficacy and safety of treprostinil palmitil inhalation powder, or TPIP, met its primary endpoint and all secondary efficacy endpoints.
Based on the results of the study, Insmed said it will immediately engage with the Food and Drug Administration about a Phase 3 trial design.
The company plans to start a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease before the end of the year, as well as a Phase 3 trial in patients with pulmonary arterial hypertension in early 2026.
"The statistically significant and clinically meaningful results shown with TPIP in pulmonary arterial hypertension mark a potential breakthrough for patients and the future of prostanoid therapy," Chief Product Strategy Officer Gene Sullivan said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
June 10, 2025 08:38 ET (12:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。